[Effect of thymalin on the status of immunogenesis and hemostasis in patients with ischemic heart disease].
It was established that the use of thymalin in multimodality therapy of CHD patients suffering from attacks of angina pectoris of effort and at rest brought back to normal the state of cellular and humoral immunity, slowed down blood coagulation, decreased fibrinogen and FDP concentration, enhanced total euglobulin and Hageman-dependent fibrinolysis. A more rapid disappearance of the pain syndrome was noted in these patients as compared to those who had not received the drug.
D000328:Adult; D000368:Aged; D001402:B-Lymphocytes / Q000276:immunology; D001777:Blood Coagulation / Q000187:drug effects*; D003327:Coronary Disease / Q000097:blood / Q000276:immunology / Q000628:therapy*; D004406:Dysgammaglobulinemia / Q000628:therapy; D005260:Female; D006801:Humans; D007136:Immunoglobulins / Q000032:analysis; D007958:Leukocyte Count / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D013601:T-Lymphocytes / Q000276:immunology; D013951:Thymus Hormones / Q000627:therapeutic use*
D007136:Immunoglobulins; D013951:Thymus Hormones; C032805:thymalin
Vliianie timalina na sostoianie immunogeneza i gemostaza u bol'nykh ishemicheskoĭ bolezn'iu serdtsa.